Bioniche Life Science fka BNC (BNC)

[DollerHero]

***** DONT MISS THE BIG OPPORTUNITY *****

Urocidin (Bladder cancer) PIII results in 2Q 2010 .Urocidin has BLOCKBUSTER POTENTIAL !!!!


Bioniche Life Science (BNC.TO)

Market Cap: 105 Mio C$
Cash: 30 Mio C$
Price: 1,21 C$


Upcoming Milestones

2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM

2010 First U.S. sales of E. coli cattle vaccine

2010 Results of refractory Phase III bladder cancer trial

2011 Belleville, ON vaccine manufacturing centre operational



Insider activity
http://canadianinsider.com/coReport/allTransactions.php?ticker=bnc



Urocidin Potential New Treatment for Bladder Cancer
http://www.associatedcontent.com/article/1939454/urocidin_potential_new_treatment_for_pg3.html?cat=70


Urocidin (Bladder Cancer) PII Results
http://www.medicalnewstoday.com/articles/139517.php



Discussion board of people dealing with bladder cancer and discussing BCG treatment and MCC
http://www.inspire.com/groups/bladder-cancer-advocacy-network/discussion/bcg-protocol/?page=1#replies





Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf



1,50 $ TGT by Haywood
http://www.haywood.com/pdffiles/BNCJul142009.pdf


SECTOR OUTPERFORM; Target: $1.50 Risk: SPECULATIVE

Partnership Agreement Puts BNC Back on Track

ALPHA: We see significant upside to investors. BNC's share price

reflects a value for the Animal Health division only - that is at 5x

2009 EBITDA or
.50/shr. We note the US$20M upfront from the Endo

agreement is worth ~
.25/shr alone. We disagree with the market that

the Human Health division with Urocidin is currently worth zero to BNC and investors



Bioniche shares
jump 34% on Endo taking up global rights
February 12, 2010 by biotuesday
http://biotuesday.ca/2010/02/12/bioniche-shares-jump-34-on-endo-taking-up-global-rights/